ELPEN has established a subsidiary company in the United Arab Emirates, specifically in Dubai, expanding its activity abroad in one of the fast-growing healthcare markets.

As announced, this is an important strategic step for the company, which aims to further strengthen its presence in the Middle East market and is implemented on the basis of its long-term commitment in the field of extroversion.

As noted in the same announcement, initially focusing on the six Gulf countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates), ELPEN has already entered into partnerships with the most important companies operating in these countries with the aim of marketing pharmaceuticals products starting from the Cardiology and Respiratory sector. By maintaining the partnerships it has had for years in this region and creating new partnerships, ELPEN seeks to promote and market its medicines in these regions, serving its vision of offering innovative treatments to patients who need them.

Extroversion is an important element of ELPEN’s philosophy. Its export activities began in the 1990s, while since 2012 it has owned ELPEN Pharma GmbH, a subsidiary company in Germany, a country in which it has been known for years for the quality and reliability of its signature medicines. Today, ELPEN products are exported to more than 90 countries worldwide. Also noteworthy is the fact that over the last two years the company has achieved a 200% increase in sales from markets outside of Greece.

Referring to the establishment of ELPEN’s subsidiary company in the UAE, Mr. Lefteris Tryfon, Chief Operating Officer of ELPEN, emphasized “In recent years at ELPEN we have been making a big leap into international markets. Utilizing our innovative products, our quality production, but also the know-how we have acquired, we have achieved a significant increase in our exports. With a clear mapping of the drug market, we approach targeted regions and partners, launching a large number of new products every year. In this context, with the establishment of our subsidiary in Dubai, we are paving the way for the Middle East markets. The main reasons we chose the specific region are: i) the dynamics of the market through increasing life expectancy, ii) the preference of health scientists and patients for European products, but also iii) the stable pricing and reimbursement framework of the products. Already the first samples are positive and we aim for the ELPEN name and products to enter the market dynamically.